About US
Contact us
-
The stichting strikes back: Mylan's Dutch foundation snaps up shares to block Teva buyWannabe acquirer Teva ($TEVA) has built up a 4.6% stake in generics rival Mylan ($MYL)--and that's enough for the newly Dutch pharma. Mylan's independent foundation--known in Dutch as a stichting--has2015/7/24
-
Novartis whacks 3 Sandoz plants, 770 jobs, despite generic units' sales growthA 10% revenue expansion in Novartis' ($NVS) generics unitSandozwas one of the positives in the Swiss drugmaker's second quarter earnings, but it will not keep the drugmaker from closing three Sandoz p2015/7/24
-
CFDA releases 2014 Annual Report for National Medical Device Adverse Event MonitoringChina Food and Drug Administration (CFDA) recently released the 2014 Annual Report for National Medical Device Adverse Event Monitoring, which includes the general situation of medical device adverse2015/7/23
-
Genzyme's Cerdelga success bodes well for Fabry prospectSanofi's ($SNY)Genzymeis testing an oral drug forFabry disease, which would go up against its own Fabrazyme if and when it wins approval. But the company knows a thing or two about bringing new pills2015/7/23
-
New obesity meds 'pretty safe,' but some side effects bear watching: AdverseEventsCardiac safety concerns forobesitydrugs aren't a new phenomenon: Fen-Phen and Meridia were notoriously yanked from shelves for troubling side effects. But companies selling a new generation of drugs--2015/7/23
-
CFDA issues three Appendixes for Good Manufacturing Practice for Medical DevicesIn order to strengthen the supervision and management of medical devices, improve enterprises' quality management level and ensure the safety and effectiveness of medical devices, China Food and Drug2015/7/22
-
Amgen's Neupogen won't face Novartis biosim till September: courtNovartis' ($NVS)Sandozmay have the firstFDA-approved biosimilar inZarxio, but it doesn't have permission to launch--and it won't be getting that until September, the country's top patent court ruled T2015/7/22
-
Bristol-Myers' next-gen HIV med gets FDA 'breakthrough' designationBristol-Myers Squibb ($BMY) nabbed a "breakthrough" tag from the FDA for its next-genHIVtherapy aimed at patients who become resistant to the drugs now in use. The U.S.-based company now gains an insi2015/7/22
-
CFDA releases 2014 Annual Report for National Adverse Drug Reaction MonitoringChina Food and Drug Administration (CFDA) recently released the 2014 Annual Report for National Adverse Drug Reaction Monitoring. In 2014, the national adverse drug reaction monitoring network receive2015/7/21
-
New long-acting Baxalta med bests Advate in hemophilia ANewly independentBaxaltarelies heavily on hemophilia sales, particularly its top-selling Advate. As competition heats up in that market, the company has something new to brag about: Its Advate follow-2015/7/21